Although we’ve come a long way as a culture in destigmatizing therapy, there are still many lingering myths and misunderstandings that shape how people think about the process. From incorrect beliefs ...

The research revealed serious flaws that could allow cyber attackers to access private therapy transcripts, mood logs, ...

Days after FDA Commissioner Marty Makary appeared to malign uniQure’s AMT-130 in an interview with CNBC, the agency confirmed ...

NEW YORK, NY / ACCESS Newswire / March 6, 2026 / Emerging Growth Research today announced the release of its Flash ...

RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history ...

This is a developing story. Please check back for updates. | After a tumultuous tenure marked by recent clashes with the biopharma industry, Vinay Prasad, M.D., will be departing his post as the FDA’s ...

Shares of uniQure N.V. QURE plunged 31.8% in a week, primarily after the company announced a disappointing regulatory update ...

While the FDA appears to be adamant that uniQure conduct a sham surgery–controlled Phase 3 trial before AMT-130 can be ...

Off-campus mental health resources include a 24/7 hotline, outpatient therapy and an intensive outpatient program.

Agency staff "strongly recommended" a sham surgery-controlled trial be conducted before an approval filing, a stance one analyst called a "worst case scenario" for UniQure.

Regenxbio (RGNX) hit by FDA CRL for RGX-121; valuation discount, cash runway to 2027, risks vs RGX-202 upside. Click here to ...

At Students' Council on February 10, Farah Elgaweesh presented on concerns from the HSSA, and Ewan Hussler became the ...